

21 February 2024

To: Diabetes specialist services within England

Dear colleague

Preparing for the implementation of Hybrid Closed Loop technologies: Update on HCL collection

We sent a letter in December 2023 notifying you of the publication of NICE's final technology appraisal guidance: [Hybrid closed loop systems for managing blood glucose levels in type 1 diabetes \(TA943\)](#).

On 22 January 2024, NHS England published its [5 year Hybrid Closed Loop implementation strategy](#) and set out an intent to utilise National Diabetes Audit (for adult services) and National Paediatric Diabetes Audit (for children and young people's services) to measure uptake, equitable access and effectiveness of HCL. The strategy also outlines how the national audits will be used to calculate NHS England's funding contribution towards the reimbursement of incremental costs that all ICBs will have the opportunity to access in 2024/25.

The strategy also included the date of 29 March 2024 as the deadline to submit baseline, pre-implementation data to both national audits. On the advice of the NDA and NPDA teams we have postponed the timeline in order to give clinical teams more time to submit the data. The revised timelines are set out in the guidance below.

This letter provides an update on the requirements of the baseline submission and guidance on what children, young people and adults diabetes services need to submit.

Guidance for paediatric diabetes teams

Since the NPDA is already collecting data on the use of HCL systems, there are no additional reporting requirements for paediatric diabetes teams over and above what they already submit as part of the core NPDA. Teams should continue to submit the complete, core NPDA dataset via the NPDA data capture system. The deadline to submit data for the purposes of NPDA quarterly reporting and provision of baseline data on HCL use has been extended from 31 March to **18 April** to align with the NDA (adult diabetes audit reporting schedule). Teams will have until 23 May to submit their final NPDA dataset for the audit year 2023/24. Future quarterly updates will be reported and shared with NHS England in line with existing NPDA quarterly reporting plans and requirements.

Guidance for diabetes centres providing specialist adult services

A comprehensive baseline of CGM and insulin pump use is required at an individual person level in order to understand each ICB's position and set indicative budgets for ICB reimbursement funding. It is requested that all adult diabetes specialist services in England provide information on *all type 1 diabetes patients using glucose technology supplied by specialist services (non-GP prescribed) as of 31 March 2024*.

In addition, we want to ensure that the eligible population for each ICB is as accurate as possible. Specialist services have an important role in correctly classifying type of diabetes. The NDA has a diagnosis validation algorithm based on recorded diagnosis and medication

records. So if it is possible, please submit all people with a confirmed diagnosis of type 1 diabetes, including those not using glucose technology. The eligible cohort for each ICB will be determined by using the validation algorithm after combining the specialist services data collection with GP data.

Details of how to register to submit data on the Clinical Audit Platform and the data items required for the collection can be found on the NDA website: [National Diabetes Audit Type 1 diabetes data reporting – Hybrid Closed Loop implementation](#).

Revised submission timeline for specialist adult diabetes teams

We previously advised that the final date for data to be reported is 29 March 2024. The revised timeline for returning the data through the Clinical Audit Platform is **Thursday 18 April 2024**. This is to allow services time to provide data for patients seen up to 31 March 2024.

Please note: To receive independent specialist service reports the NDA collection is required by 23 May 2024. If you are able and wish to do so, you can submit your full audit data for the period 1 January 2023 to 31 March 2024 with the glucose technology baseline collection and this will be used as your return.

Future reporting

We intend to set up a quarterly collection for capturing HCL uptake. Diabetes services will be asked to complete these returns. This data will be used to measure achievement and calculate NHS England's contribution to reimbursement costs.

More information on the data items required and timelines for quarterly submission will be communicated in due course.

Yours faithfully

Professor Partha Kar

NHS England GIRFT Diabetes Co-Lead &
Type 1 Diabetes Technology Clinical Lead

Dr Fulya Mehta

Children and Young People's Diabetes
Clinical Lead
NHS England

Dr Bob Young

Clinical Lead, National Diabetes Audit

Professor Justin Warner

Clinical Lead, National Paediatric Diabetes
Audit